<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01430481</url>
  </required_header>
  <id_info>
    <org_study_id>H-1-2011-018</org_study_id>
    <nct_id>NCT01430481</nct_id>
  </id_info>
  <brief_title>Rosehip Powder for Knee Osteoarthritis</brief_title>
  <official_title>Comparing Different Preparations and Dosages of Rosehip Powder in Patients With Painful Osteoarthritis of the Knee: An Exploratory Randomised Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Frederiksberg University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Axellus</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Oak Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Frederiksberg University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to compare three combinations of preparations in a comparative trial
      program on rosehip powder for knee OA. The trial is a comparative, 12-week, randomized,
      double-blind, active-controlled trial, designed to determine the comparative efficacy and
      safety of these preparations in patients with pain from knee OA.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Complementary or alternative therapies (incl. nutraceuticals - functional ingredients sold as
      powders, pills, and other medicinal forms not generally associated with food) for OA are
      commonly used, and it is therefore important that health care providers are aware of the
      evidence supporting the claims. One proposed nutraceutical which has shown promising results
      in OA patients, is the hip powder of Rosa canina.

      The findings from a previous meta-analysis of rosehip powder from Rosa canina for symptomatic
      treatment of OA was a small but potentially relevant reduction of pain and a statistically
      significant reduction in use of analgesics.

      The present study is undertaken to compare two different products, one of which is tested in
      two different doses, in a non-inferiority design.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Actual">January 2014</completion_date>
  <primary_completion_date type="Actual">January 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain, Walking on flat surface - range: 0-100</measure>
    <time_frame>week 12</time_frame>
    <description>Knee injury and Osteoarthritis Outcome Score (KOOS) subscale item</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain - range: 0-100</measure>
    <time_frame>week 12</time_frame>
    <description>KOOS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptoms - range: 0-100</measure>
    <time_frame>week 12</time_frame>
    <description>KOOS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Function in daily living - range: 0-100</measure>
    <time_frame>week 12</time_frame>
    <description>KOOS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Knee related Quality of life - range: 0-100</measure>
    <time_frame>week 12</time_frame>
    <description>KOOS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VAS Pain - 0-100</measure>
    <time_frame>week 12</time_frame>
    <description>VAS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VAS Disability - 0-100</measure>
    <time_frame>week 12</time_frame>
    <description>VAS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VAS patient global assessment of disease status - 0-100</measure>
    <time_frame>week 12</time_frame>
    <description>VAS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VAS physician global assessment of disease status - 0-100</measure>
    <time_frame>week 12</time_frame>
    <description>VAS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical component summary - range: 0-100</measure>
    <time_frame>week 12</time_frame>
    <description>Short-Form-36 score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mental component summary - range: 0-100</measure>
    <time_frame>week 12</time_frame>
    <description>Short-Form-36 score</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">150</enrollment>
  <condition>Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>Standard Rosehip Powder (A)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>6 capsules of standardized hip powder of Rosa canina made from the seeds and husks of the fruits from a subtype of R. canina hip powder (i.e., rosehip)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>New rosehip formulation (B)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 capsules of modified hip powder of Rosa canina made from the seeds and husks of the fruits from a subtype of R. canina hip powder (i.e., rosehip)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>New rosehip formulation in half dose (C)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 capsules of modified hip powder of Rosa canina made from the seeds and husks of the fruits from a subtype of R. canina hip powder (i.e., rosehip)</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Rosehip powder</intervention_name>
    <description>The trial is a patient and physician blinded, 12-week, randomized controlled trial (1:1:1). Participants will be randomized into one of 3 groups: 'Standard rosehip powder' (A), 'New rosehip formulation' (B), or 'New rosehip formulation in half dose' (C). Personnel responsible for data collection will be blinded to group assignment. The patients will report on their symptoms every four weeks.</description>
    <arm_group_label>Standard Rosehip Powder (A)</arm_group_label>
    <arm_group_label>New rosehip formulation (B)</arm_group_label>
    <arm_group_label>New rosehip formulation in half dose (C)</arm_group_label>
    <other_name>Rosehip</other_name>
    <other_name>Litomove</other_name>
    <other_name>Litozin</other_name>
    <other_name>HybenVital</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  40 years of age and have clinical evidence (diagnosed according to the American
             College of Rheumatology [ACR] criteria) and radiographic evidence of OA.

          -  Eligible patients have a self-reported pain level corresponding to at least 40 mm on a
             100 mm VAS when screened

        Exclusion Criteria:

          -  Patients will not be considered eligible if they are considered morbidly obese -having
             a body mass index (BMI) above 40 kg/m2, concurrent medical or arthritic conditions
             that could confound evaluation of the index joint, or coexisting disease that could
             preclude successful completion of the trial.

          -  Patients who already take a rosehip powder as a dietary supplement; have inability to
             speak Danish fluently; or have a mental state impeding compliance with the program
             will not be considered eligible for inclusion.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Henning Bliddal, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Parker Institute, Frederiksberg Hospital, Denmark</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Parker Institute, Frederiksberg Hospital</name>
      <address>
        <city>Frederiksberg</city>
        <zip>2000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <link>
    <url>http://www.parkerinst.dk</url>
    <description>The Parker Institute, Copenhagen, Denmark</description>
  </link>
  <reference>
    <citation>Altman R, Asch E, Bloch D, Bole G, Borenstein D, Brandt K, Christy W, Cooke TD, Greenwald R, Hochberg M, et al. Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association. Arthritis Rheum. 1986 Aug;29(8):1039-49.</citation>
    <PMID>3741515</PMID>
  </reference>
  <reference>
    <citation>Christensen R, Bartels EM, Altman RD, Astrup A, Bliddal H. Does the hip powder of Rosa canina (rosehip) reduce pain in osteoarthritis patients?--a meta-analysis of randomized controlled trials. Osteoarthritis Cartilage. 2008 Sep;16(9):965-72. doi: 10.1016/j.joca.2008.03.001. Epub 2008 Apr 14. Review.</citation>
    <PMID>18407528</PMID>
  </reference>
  <reference>
    <citation>Zhang W, Nuki G, Moskowitz RW, Abramson S, Altman RD, Arden NK, Bierma-Zeinstra S, Brandt KD, Croft P, Doherty M, Dougados M, Hochberg M, Hunter DJ, Kwoh K, Lohmander LS, Tugwell P. OARSI recommendations for the management of hip and knee osteoarthritis: part III: Changes in evidence following systematic cumulative update of research published through January 2009. Osteoarthritis Cartilage. 2010 Apr;18(4):476-99. doi: 10.1016/j.joca.2010.01.013. Epub 2010 Feb 11. Review.</citation>
    <PMID>20170770</PMID>
  </reference>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 29, 2011</study_first_submitted>
  <study_first_submitted_qc>September 7, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 8, 2011</study_first_posted>
  <last_update_submitted>August 9, 2016</last_update_submitted>
  <last_update_submitted_qc>August 9, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 10, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Frederiksberg University Hospital</investigator_affiliation>
    <investigator_full_name>Henning Bliddal</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>rosehip</keyword>
  <keyword>osteoarthritis</keyword>
  <keyword>pain</keyword>
  <keyword>knee</keyword>
  <keyword>RCT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

